SLCO1B1 variants are associated with decreased methotrexate clearance and increased gastrointestinal toxicity for the treatment of acute lymphoblastic leukemia (Ramsey et al., 2012). Here, SLCO1B1 is linked to acute lymphoblastic leukemia.